Oruka Therapeutics Announces Strong Phase 2a Results for ORKA-001 in Plaque Psoriasis, Outperforming Skyrizi

on

Oruka's ORKA-001 achieved 63.5% PASI 100 (complete skin clearance) at week 16 in the Phase 2a EVERLAST-A trial (40/63 patients) vs. 4.8% (1/21) on placebo.123

83% PASI 90 and 84.1% IGA 0/1 responses, with safety profile comparable to placebo and no serious adverse events in the active arm.12

Cross-trial comparisons show higher PASI 100 rates than Skyrizi (up to 51%), positioning ORKA-001 as potentially best-in-class IL-23 inhibitor with once-yearly dosing potential.13

Jefferies analysts called it an 'outright win over Skyrizi', forecasting $5-10B peak sales; shares surged 20-30%.13

Longer-term data from EVERLAST-A expected H2 2026, Phase 2b EVERLAST-B results in 2027, Phase 3 planning underway.12

Sources:

1. https://www.biopharmadive.com/news/oruka-plaque-psoriasis-drug-study-results/818527/

2. https://www.stocktitan.net/sec-filings/ORKA/8-k-oruka-therapeutics-inc-reports-material-event-2d3a9eabfb72.html

3. https://www.fiercebiotech.com/biotech/orukas-psoriasis-data-hailed-outright-win-over-skyrizi-spurring-big-blockbuster-forecasts